<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>SIMVASTATIN</b></p>

<p><b>See also: HMG-CoA reductase inhibitors (statins)</b></p>

<p><b>See also: substrates at risk of CYP3A4</b></p>

<p><b>From the French ANSM drug interactions document of </b></p>

<p><b>September 2016, pp. 199-200</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>AMIODARONE</b></p>

<p><b>RxNorm: 703 </b></p>

<p><b>ATC: C01BD01</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction</p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>AMLODIPINE</b></p>

<p><b>RxNorm: 17767 </b></p>

<p><b>ATC: C08CA01 </b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent). </p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction</p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>AZITHROMYCIN </b></p>

<p><b>RxNorm: 18631 </b></p>

<p><b>ATC: J01FA10</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. </p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Use weaker doses of the cholesterol lowering agent or another statin not affected by this type of interaction</p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01 </b></p></td>
<td valign="top"><p><b>BOCEPREVIR</b></p>

<p><b>RxNorm: 1102129</b></p>

<p><b>ATC: J05AE12</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type, due to decrease of the metabolism of the simvastatin</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>CARBAMAZEPINE</b></p>

<p><b>RxNorm: 2002 </b></p>

<p><b>ATC: N03AF01</b></p></td>
<td valign="top"><p>Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>CICLOSPORIN</b></p>

<p><b>RxNorm: 3008 </b></p>

<p><b>ATC: </b></p>

<p><b>L04AD01 S01XA18</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>CLARITHROMYCIN</b></p>

<p><b>RxNorm: 21212 </b></p>

<p><b>ATC: J01FA09 </b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. </p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>DANAZOL</b></p>

<p><b>RxNorm: 3102</b></p>

<p><b>ATC: G03XA01</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>DILTIAZEM</b></p>

<p><b>RxNorm: 3443</b></p>

<p><b>ATC: C08DB01</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent. </p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Do not exceed the dosage of 20mg/day of simvastatin. If the therapeutic objective is not reached at this dosage, use another statin not affected by this type of interaction. </p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>DRONEDARONE</b></p>

<p><b>RxNorm: 233698</b></p>

<p><b>ATC: C01BD07</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>ERYTHROMYCIN</b></p>

<p><b>RxNorm: 4053 </b></p>

<p><b>ATC:</b></p>

<p><b>D10AF02 J01FA01 S01AA17</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>RITONAVIR BOOSTED PROTEASE INHIBITORS</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>J05AE-002</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>ITRACONAZOLE</b></p>

<p><b>RxNorm: 28031 </b></p>

<p><b>ATC: J02AC02</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>KETOCONAZOLE</b></p>

<p><b>RxNorm: 6135 </b></p>

<p><b>ATC:</b></p>

<p><b>D01AC08 G01AF11 J02AB02</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</p></td>
<td valign="top"><p><b>CONTRAINDICATION </b></p>

<p>Use a statin not affected by this type of interaction</p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>ST JOHNS WORT</b></p>

<p><b>Hypericum perforatum</b></p>

<p><b>RxNorm: 258326</b></p>

<p><b>ATC: not found</b></p></td>
<td valign="top"><p>Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>OMBITASVIR + PARITAPRÉVIR</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>OMPA</b></p></td>
<td valign="top"><p>Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the therapy with ombitavir+paritaprevir</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>GRAPEFRUIT (JUICE AND FRUIT)</b></p></td>
<td valign="top"><p>Significant increase of the plasma concentrations of the cholesterol lowering agent, with risk of onset of undesirable effects, especially muscular</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>POSACONAZOLE</b></p>

<p><b>RxNorm: 282446 </b></p>

<p><b>ATC: J02AC04</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor).</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>RANOLAZINE</b></p>

<p><b>RxNorm: 35829</b></p>

<p><b>ATC: C01EB18</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Do not exceed the dosage of 20 mg/day of simvastatin or use another statin not affected by this type of interaction</p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>RIFAMPICIN</b></p>

<p><b>RxNorm: 9384 </b></p>

<p><b>ATC: J04AB02 </b></p></td>
<td valign="top"><p>Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>ROXITHROMYCIN</b></p>

<p><b>RxNorm: 9478 </b></p>

<p><b>ATC: J01FA06</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Use weaker doses of cholesterol lowering agent<b>.</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>STIRIPENTOL</b></p>

<p><b>RxNorm: 37119</b></p>

<p><b>ATC: N03AX17</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>TELAPREVIR</b></p>

<p><b>Rx Norm: 1102261 </b></p>

<p><b>ATC: J05AE11</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>TELITHROMYCIN</b></p>

<p><b>RxNorm: 274786 </b></p>

<p><b>ATC: J01FA15</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>VERAPAMIL</b></p>

<p><b>RxNorm: 11170 </b></p>

<p><b>ATC: C08DA01 </b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)</p></td>
<td valign="top"><p><b>Precaution for use</b></p>

<p>Do not exceed the dosage of 20mg/day of simvastatin or use another statin not affected by this type of interaction</p></td>
</tr>

<tr>
<td valign="top"><p><b>SIMVASTATIN</b></p>

<p><b>RxNorm: 36567 </b></p>

<p><b>ATC: C10AA01</b></p></td>
<td valign="top"><p><b>VORICONAZOLE</b></p>

<p><b>RxNorm: 121243 </b></p>

<p><b>ATC: J02AC03</b></p></td>
<td valign="top"><p>Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p></td>
</tr>

</tbody>
</table>

